PABS Annex Negotiations Advance — What It Means for Pharma Manufacturing

A draft annex on Pathogen Access and Benefit Sharing (PABS) moved closer to finalization after WHO Member States concluded a weeklong round of negotiations on 14 February 2026 — a development that could eventually impose new obligations on pharmaceutical manufacturers around intellectual property, technology transfer, and rapid-response production during future pandemic declarations. Why this matters: the PABS annex is a key component of the broader WHO Pandemic Agreement, and its final text has the potential to reshape how manufacturers engage with global health authorities when novel pathogens emerge. Plant heads, QA directors, and regulatory affairs leads at companies involved in vaccine, biologic, or antiviral production should be tracking these negotiations closely, as the resulting framework may directly affect GMP-compliant manufacturing commitments, supply chain planning, and technology-sharing arrangements during declared pandemics.

The fifth meeting of the Intergovernmental Working Group on the WHO Pandemic Agreement (IGWG) — established by the World Health Assembly (WHA) last year specifically to negotiate the PABS annex — ran from 9 to 14 February 2026. WHO characterized the discussions as productive. While the source material does not detail the specific provisions under negotiation, the PABS framework broadly addresses how pathogen samples and genomic sequence data are shared internationally and what benefits — including access to medical countermeasures — flow back to contributing countries. For manufacturers operating under ICH Q10 quality management systems and 21 CFR Part 211 requirements, the practical question is whether the final annex will create binding commitments around production allocation, licensing terms, or technology transfer that must be factored into process validation strategies and capacity planning.

The implications extend across several operational domains. If the PABS annex establishes mandatory benefit-sharing mechanisms tied to pandemic declarations, manufacturers may need to build contractual and operational flexibility into their facility planning — particularly at sites designated for surge or rapid-response production. Sterility assurance protocols, supply chain qualification, and regulatory filing strategies for pandemic-use products could all be affected depending on the scope of obligations the final text imposes. Companies with global manufacturing footprints should consider how differing national implementations of a PABS framework might create divergent regulatory expectations across jurisdictions.

It is important to note that the PABS annex remains under negotiation and no final text has been agreed upon. The IGWG process is ongoing, and the specific obligations that may apply to pharmaceutical manufacturers will depend on the outcome of subsequent negotiating rounds and eventual adoption by the World Health Assembly. Regulatory affairs teams would be well served to monitor IGWG outputs and begin internal assessments of how various proposed provisions could intersect with existing GMP compliance frameworks, site master files, and pandemic preparedness plans.

Source: World Health Organization news release, 17 February 2026. Pharma Now will continue to track IGWG negotiations and report on developments relevant to manufacturing and regulatory compliance.